23 January 2023
Top hires for VC & PE portfolio companies Q4-2022
Search Highlights
Recent top global hires for Venture Capital and Private Equity backed companies, covering a broad range of disciplines and sectors across Life Sciences, Health, and Tech.
This quarter’s successful placements include:
| Function | Focus area | Location |
|---|---|---|
| CEO | Regenerative medicine | UK |
| CEO | Implantable cardiac devices | France |
| Chief Business Officer | Neurodegenerative diseases | Netherlands |
| Chief Medical Officer | Age-related therapeutics | US |
| Chief Financial Officer | RNA-based therapeutics | Germany |
| SVP, GM Biosurgery & EMEA Sales | Surgical equipment | Belgium |
| Head of Regulatory Affairs | In vivo gene editing | US |
| Country CEO | Veterinary services | Nordics |
| UK General Manager | Digital devices and therapeutics | US |
| VP Immunology / Translation | Small molecule therapeutics | UK |
| VP Global Leader of Manufacturing and Operations | DNA sequencing | UK |
| Head of Product | AI-enabled analytics | Belgium |
| 2 x Board Directors | Infectious Diseases | UK |
| Chair | Active Pharmaceutical Ingredients (APIs) | Switzerland |
Newly opened projects include:
| Function | Focus area | Location |
|---|---|---|
| CEO | RNA vaccines | UK |
| CEO | Vaccines | Switzerland |
| CEO | Specialist CRO | Australia |
| Chief Business Officer | Precision medicines | US |
| Chief Scientific Officer | Retinal vascular diseases | Nordics |
| Chief Technology Officer | AAV gene therapy | US |
| Chief of Staff | Ophthalmic medical devices | France |
| Chief Technology & Operations Officer | Plant-based foods | Nordics |
| VP, Antibody Engineering & Protein Sciences | Drug discovery services | US |
| Head of Translational Medicine | Cell therapy biotech | Switzerland |
| VP Business Development Oncology | Quantum physics enabled drug development | US |
| Investment Manager Digital Health | VC investor | Netherlands |
| Chair | AI for drug discovery | Central & Eastern Europe |